Seventeen analysts currently cover The Clorox Company, settling on a consensus "hold" rating as of our data-as-of timestamp late yesterday evening. The stock is currently priced at $94.75, with the aggregate mean price target resting at $104.47, suggesting a potential upside of 10.3%. This evaluation comes during a period of active repricing, characterized by downward adjustments from major firms including Wells Fargo, Barclays, and UBS earlier this spring. The sentiment remains cautious, reflecting a market that is weighing the firm's forward P/E of 15.50 against a beta of 0.531, which underscores the relative stability often sought in this defensive corner of the market.
What analysts show
The current consensus target implies a moderate appreciation path, yet the recent history of price target revisions provides a clearer picture of the skepticism currently held by institutional observers. Specifically, Barclays moved its target down to $85, while UBS reduced its outlook from $110 to $96 in early May. This activity suggests that despite the 10.3% upside, the "hold" consensus is anchored by a desire to see how operational results align with guidance heading into the next earnings cycle on August 3. Interestingly, insider activity has been two-sided, with 3 meaningful buys totaling 13,000 shares contrasted against 4 meaningful sells totaling 26,249 shares. This narrow gap between buying and selling volume among insiders mimics the indecision seen among sell-side analysts, who seem to be waiting for a more definitive catalyst before adjusting their long-term models.
Sector context
Within the broader consumer-staples landscape, Clorox currently occupies the 12th rank in terms of implied upside, sitting marginally above the sector average of 9.9%. While a 10.3% upside is respectable in a defensive sector, it pales in comparison to other household names, such as STZ, which carries a 30.2% implied upside, or HSY, currently sitting at 24.5%. That spread matters because it highlights a clear bifurcation in how the market is pricing growth versus yield-focused plays. While the 5.22 dividend provides a buffer for shareholders, the lower-than-peer upside potential suggests that the market is currently prioritizing companies with more aggressive growth trajectories or those deemed better positioned to navigate rising input costs. Clorox remains a focal point for those monitoring the interplay between staple consumption and valuation compression.